Guo Jun-Hui, Wang Yuan-Yuan, Zhang Jiang-Wei, Liu Pei-Min, Hao Yan-Jun, Duan Hai-Rui
Department of Oncology, The Second Affiliated Hospital of Henan University of Chinese Medicine, Henan Province Hospital of TCM, Zhengzhou 450002, Henan Province, China.
World J Clin Cases. 2020 Apr 6;8(7):1326-1336. doi: 10.12998/wjcc.v8.i7.1326.
Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. Apatinib has demonstrated encouraging antitumor activities. This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases.
We report two patients with multiple brain micrometastases after failure of second-line treatment. Both patients had extracerebral metastases. When the patients took 250 mg/d apatinib orally, the intracerebral lesions disappeared. The extracerebral lesions were partially alleviated. Both patients had a progression-free survival of more than 12 mo and were still stable. The safety was good. The main adverse events (AEs) were mild hypertension and proteinuria, which could be controlled.
Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment.
阿帕替尼是一种小分子多靶点酪氨酸激酶抑制剂。阿帕替尼已显示出令人鼓舞的抗肿瘤活性。本研究旨在观察阿帕替尼治疗多发性脑微转移瘤的疗效和安全性。
我们报告了2例二线治疗失败后发生多发性脑微转移瘤的患者。两名患者均有脑外转移。当患者口服阿帕替尼250mg/d时，脑内病变消失。脑外病变部分缓解。两名患者的无进展生存期均超过12个月，且病情仍稳定。安全性良好。主要不良事件为轻度高血压和蛋白尿，可得到控制。
阿帕替尼对二线治疗失败后的多发性脑微转移瘤患者有明确疗效且耐受性良好。
